SV112 · SV-Delivery™
SV112 Delivery™ Lymphatic trafficking LNP
Listed · 实验数据待补
Sold on the SunVax store as "Lipid Nanoparticle R&D". The technical descriptor on this page (above) comes from SunVax conference 2026-05-03 slide 2.
Species
Cross
Primary target
lymphatic (淋巴循环)
Applications
in vivo
Cargo compatibility
mRNA
Particle size
—
Freeze-thaw cycles tested
—
Data we are still collecting for SV112
SunVax has not yet publicly disclosed efficacy, dose, or stability numbers for this kit at the same depth as SV101 / SV106. Rather than fill the table with inferred (grade C) numbers, we leave it explicit:
- No published in vitro transfection percentage for the primary target cell.
- No published in vivo (animal model) decay curve.
- No public freeze-thaw stability cycle count.
- No public encapsulation efficiency on this kit's lot.
If you need any of these data points to plan an experiment, contact the SunVax partnership team — they will share what is available under NDA.
Highlights
- Lymph node targeting · 适合 cancer vaccine 与 immune priming
Sources used on this page
- SunVax conference presentation 2026-05-03 · slide 2 (kits portfolio) and slide 3 (efficacy / stability data).
- SunVax product catalog at sunvaxmrna.com (last verified 2026-05-16).
To request a correction or to ask for additional documentation on this kit, email yingzhongli@sunvaxmrna.com.